Idiopathic inflammatory myopathy
Clinical trials for Idiopathic inflammatory myopathy explained in plain language.
Never miss a new study
Get alerted when new Idiopathic inflammatory myopathy trials appear
Sign up with your email to follow new studies for Idiopathic inflammatory myopathy, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise for Long-Term control of rare muscle disease
Disease control By invitation onlyThis study tests the long-term safety of a drug called efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy, a group of rare muscle diseases. Participants who completed a previous trial will receive the drug as a shot under the skin for up to 51 months. The…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Sep 21, 2026 18:00 UTC
-
Immune system overhaul: could CAR T-Cells tame autoimmune disease?
Disease control OngoingThis early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase 1 • Sponsor: David Porter • Aim: Disease control
Last updated Sep 21, 2026 18:00 UTC
-
Gene therapy shot aims to tame autoimmune diseases in early trial
Disease control OngoingThis early-phase study tests a single injection of a gene therapy called V001-BCMA for people with autoimmune diseases like lupus that have not responded to standard treatments. The therapy targets and modifies specific immune cells to reduce disease activity. The main goal is to…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Early phase 1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control OngoingThis early-stage trial is testing a new treatment called CC-97540, which uses a patient's own immune cells modified to target and destroy faulty immune cells. It is for people with severe forms of lupus, myositis, scleroderma, or rheumatoid arthritis that have not improved with s…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase 1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control By invitation onlyThis early-stage trial is testing a new treatment called KITE-363 for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. KITE-363 is a type of cell therapy where a patient's own immune cells are modified in a lab to t…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase 1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immune cell therapy aimed at autoimmune diseases hits early snag
Disease control CancelledThis early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Early phase 1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC